openPR Logo
Press release

Thyroid Cancer Pipeline Outlook Report 2024 (Updated)

04-15-2024 06:01 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Thyroid Cancer Pipeline

Thyroid Cancer Pipeline

DelveInsight's, "Thyroid Cancer Pipeline Insight 2024" report provides comprehensive insights about 40+ Thyroid Cancer companies and 40+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Thyroid Cancer Pipeline Report
• DelveInsight's Thyroid Cancer Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline treatment therapies.
• The leading companies working in the Thyroid Cancer Market include Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
• Promising Thyroid Cancer Pipeline Therapies in the various stages of development include Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
• April 2024: Beijing Scitech-Mq Pharmaceuticals Limited announced a study of Phase 2 clinical trials for ST-1898 tablets. ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc. The primary purpose of this study is to evaluate the efficacy of ST-1898 tablets in patients with locally advanced or metastatic RAIR-DTC after failure of at least first-line TKI systemic therapy. All subjects will receive ST-1898 180 mg orally once daily until disease progression or intolerable toxicity.
• April 2024: Hoffmann-La Roche announced a study of Phase 1 & 2 clinical trials for pralsetinib (BLU-667). This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

Request a sample and discover the recent advances in Thyroid Cancer Treatment Drugs @ Thyroid Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Thyroid Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Thyroid Cancer Overview
Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer. There are more than 50,000 new cases of thyroid cancer each year in the United States. Women are more likely to develop thyroid cancer at a ratio of three to one.

Find out more about Thyroid Cancer Therapeutics Assessment @ Thyroid Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Thyroid Cancer Emerging Drugs Profile
• Donafenib: Suzhou Zelgen Biopharmaceuticals
• Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
• Nivolumab: Bristol-Myers Squibb
• RX208: Suzhou NeuPharma
• AIC100: AffyImmune Therapeutics

Thyroid Cancer Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the Thyroid Cancer therapies. The Thyroid Cancer companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals.

Request a sample and discover the recent advances in Thyroid Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Thyroid Cancer Segmentation- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Thyroid Cancer Drugs and Companies
• Rosiglitazone: Exelixis
• Lenvatinib: Eisai Limited
• Ifosfamide: Merck Sharp & Dohme LLC

Thyroid Cancer Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Thyroid Cancer Therapeutics Market include-
Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.

Dive deep into rich insights for drugs for Thyroid Cancer Pipeline, click here @ Thyroid Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Thyroid Cancer Pipeline Report
• Coverage- Global
• Thyroid Cancer Companies- Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
• Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Thyroid Cancer Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Thyroid Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Thyroid Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Donafenib: Suzhou Zelgen Biopharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nivolumab: Bristol-Myers Squibb
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AIC100: Affyimmune Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Thyroid Cancer Key Companies
21. Thyroid Cancer Key Products
22. Thyroid Cancer- Unmet Needs
23. Thyroid Cancer- Market Drivers and Barriers
24. Thyroid Cancer- Future Perspectives and Conclusion
25. Thyroid Cancer Analyst Views
26. Thyroid Cancer Key Companies
27. Appendix

List of Important Links-
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Thyroid Cancer Pipeline Outlook Report 2024 (Updated) here

News-ID: 3464552 • Views:

More Releases from DelveInsight Business Research LLP

Glioblastoma Market Size in the 7MM is approximately USD XX Million in 2023, estimates DelveInsight
Glioblastoma Market Size in the 7MM is approximately USD XX Million in 2023, est …
The Glioblastoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2034). Furthermore, launching various multiple- Glioblastoma pipeline products will significantly revolutionize the Glioblastoma market dynamics" The Glioblastoma market report provides current treatment practices, Glioblastoma emerging drugs, market share of individual therapies, and current and forecasted 7MM Glioblastoma market size from 2020 to 2034. The report also covers current Glioblastoma treatment market practices/algorithms
Chronic Hepatitis B Market Size was approximately USD 1,500 Million in 2022, estimates DelveInsight
Chronic Hepatitis B Market Size was approximately USD 1,500 Million in 2022, est …
"The Chronic Hepatitis B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2034). Furthermore, launching various multiple- Chronic Hepatitis B pipeline products will significantly revolutionize the Chronic Hepatitis B market dynamics" The Chronic Hepatitis B market report provides current treatment practices, Chronic Hepatitis B emerging drugs, market share of individual therapies, and current and forecasted 7MM a Chronic Hepatitis B market size
Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2024 (Updated)
Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2024 (Up …
DelveInsight's, "Alopecia Areata Pipeline Insight 2024" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Alopecia Areata Pipeline Report •
Plaque Psoriasis Pipeline Insights, FDA Approvals, Clinical Trials Assessment, and Companies 2024
Plaque Psoriasis Pipeline Insights, FDA Approvals, Clinical Trials Assessment, a …
DelveInsight's, "Plaque Psoriasis Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Plaque Psoriasis pipeline landscape. It covers the Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Plaque Psoriasis Pipeline Report •

All 5 Releases


More Releases for Thyroid

Thyroid Cancer Treatment Market Increasing Ageing Population and Thyroid Cancer …
The thyroid cancer treatment market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029 on account of the increasing healthcare expenditure and the rising prevalence of thyroid cancer. As per The American Society of Clinical Oncology, in 2020, 44,280 number of adults in the United States is estimated to suffer from thyroid cancer. Such increasing prevalence of thyroid cancer is further expected to drive the
Thyroid Gland Disorders Treatment Market Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of
Thyroid Gland Disorder Treatment Market: Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
The number of patients suffering from thyroid gland disorders across the globe is increasing at a rapid rate. This direct increase in demand is expected to be a primary driver for the development of thyroid gland disorder treatments. The number of patients with thyroid gland disorder is increasing due to a growing population of the elderly, who are prone to thyroid disorders and similar illnesses. Additionally, a person suffering from